N/A
N=192
Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial
Obstetric Labor, Premature
Bottom Line
View on ClinicalTrials.gov: NCT00185900 ↗Enrolled (actual)
192
Serious AEs
19.3%
Results posted
Oct 2018
Primary outcome: Primary: Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence — 80; 72 Participants — p=0.01
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Magnesium Sulfate (Drug); Nifedipine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Stanford University
- Primary completion
- Jul 2005
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence |
80; 72 | 0.01 sig |
| SECONDARY Time to Uterine Quiescence |
8.4; 6.1 | — |
| SECONDARY Gestational Age at Delivery |
35.8; 36.0 | — |
| SECONDARY Neonatal Birth Weight |
2550; 2650 | — |
| SECONDARY Serious Maternal Adverse Effect |
20; 10 | — |
| SECONDARY Composite Neonatal Morbidity |
27; 22 | — |
Summary
To compare intravenous magnesium sulfate to oral nifedipine for acute tocolysis of preterm labor
Eligibility Criteria
Inclusion Criteria::- Uterine contractions and cervical change or ruptured membranes in a preterm gestation Exclusion Criteria:- placental abruption, fetal distress, placenta previa, maternal medical contraindication to tocolysis
Data sourced from ClinicalTrials.gov (NCT00185900). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.